Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:20:35·⟳ 抓取 19:21:05 +30s·⚡ 决策 10-21 19:23:54 +2m49s·6.1 天前
INmune Bio向英国MHRA提交Ebstrocel最终pre-MAA材料包，完整MAA改为2027年2月一次性提交
本条Investing.com报道与11:19 UTC已处理的GlobeNewswire通稿为同一具体催化（同一pre-MAA材料包、同一2027年2月MAA/Q2 BLA时间线、同一约6周提前口径），无金额、指引或监管状态的新增事实；正文标题还误挂SpaceX/Tesla合并句，系AI生成页面串标题，正文实体为INMB。按跨源查重规则输出AVOID，不再重复Web/行情/先例研究。
📄 原文Investing.com↗ 原文
INmune Bio submits pre-approval package to UK regulator for RDEB
SpaceX, Tesla shares rise after Musk says committees exploring possible merger BOCA RATON, Fla. - INmune Bio Inc. (NASD…
不做 INmune Bio Inc.（INMB.US）
同一pre-MAA催化已在2分钟前据GlobeNewswire一手通稿研判为不做（程序性里程碑、正式MAA在2027年2月、无近期财务增量、微盘低流动性且需大额融资）；本条Investing.com为AI生成二手转述、无新增事实，重复信号不再交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
INmune Bio提交MHRA pre-MAA材料包属正式申报前的程序性步骤（非受理/批准），且该催化2分钟前已据一手通稿研判为风险回报不足；本条二手AI转述无新增信息，不做。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 medium ↗
主要风险
- Ebstrocel仍处临床开发阶段，pre-MAA不等于MAA受理或批准，MHRA验证/补件与FDA会议反馈均存在不确定性。
- INMB为无收入微盘生物科技股，正式申报在2027年，后续依赖大额融资，存在稀释与流动性风险。
先例如何影响了这次决策
对本次决策的影响:同一催化已在首发节点完成研判并判不做，本条为重复二手信号，未重复外部先例检索；不改变结论。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,623 ms
{"result": "search_processed_events:agent query=`inmb uk regulator submission cell therapy recessive dystrophic epidermolysis bullosa | inmune bio ebstrocel mhra pre-marketing authorisation application rdeb | inmune bio pre-maa p`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、22265 条本臂决策(完整)，返回 1 条候选。\n• 10-2
原文全文
展开原文 · 2,061 字
SpaceX, Tesla shares rise after Musk says committees exploring possible merger
BOCA RATON, Fla. - INmune Bio Inc. (NASDAQ:INMB) submitted its final pre-Marketing Authorisation Application package to the UK Medicines and Healthcare products Regulatory Agency on Sunday for Ebstrocel, its investigational cell therapy for recessive dystrophic epidermolysis bullosa, according to a press release statement.
The company plans to submit a full Marketing Authorisation Application in early February 2027. INmune Bio revised its regulatory submission strategy from a sequential rolling submission previously planned to begin in late 2026 to a complete application submission. The company stated this approach could accelerate potential UK approval by approximately six weeks compared with the previously anticipated timeline.
The company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information.
"This is a remarkable achievement by the whole CMC team and our external regulatory advisors allowing us to accelerate the potential approval for Ebstrocel for children with RDEB," said Mark Lowdell, Chief Scientific Officer of INmune Bio.
INmune Bio has engaged U.S. regulatory advisors to prepare and submit a Type B meeting request to the U.S. Food and Drug Administration. Subject to feedback from that meeting, the company plans to submit a Biologics License Application in the second quarter of 2027.
David Moss, Chief Executive Officer of INmune Bio, said the company is prioritizing its FDA application ahead of a European Medicines Agency submission. Ebstrocel has received U.S. Orphan Drug and Rare Pediatric Disease designations.
Ebstrocel is a pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy. The product candidate remains in clinical development stage and has not been approved by regulatory authorities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOCA RATON, Fla. - INmune Bio Inc. (NASDAQ:INMB) submitted its final pre-Marketing Authorisation Application package to the UK Medicines and Healthcare products Regulatory Agency on Sunday for Ebstrocel, its investigational cell therapy for recessive dystrophic epidermolysis bullosa, according to a press release statement.
The company plans to submit a full Marketing Authorisation Application in early February 2027. INmune Bio revised its regulatory submission strategy from a sequential rolling submission previously planned to begin in late 2026 to a complete application submission. The company stated this approach could accelerate potential UK approval by approximately six weeks compared with the previously anticipated timeline.
The company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information.
"This is a remarkable achievement by the whole CMC team and our external regulatory advisors allowing us to accelerate the potential approval for Ebstrocel for children with RDEB," said Mark Lowdell, Chief Scientific Officer of INmune Bio.
INmune Bio has engaged U.S. regulatory advisors to prepare and submit a Type B meeting request to the U.S. Food and Drug Administration. Subject to feedback from that meeting, the company plans to submit a Biologics License Application in the second quarter of 2027.
David Moss, Chief Executive Officer of INmune Bio, said the company is prioritizing its FDA application ahead of a European Medicines Agency submission. Ebstrocel has received U.S. Orphan Drug and Rare Pediatric Disease designations.
Ebstrocel is a pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy. The product candidate remains in clinical development stage and has not been approved by regulatory authorities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
184f5109ff· 2026-10-21 19:23 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前